These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 8775976)

  • 1. Protein engineering of lantibiotics.
    Kuipers OP; Bierbaum G; Ottenwälder B; Dodd HM; Horn N; Metzger J; Kupke T; Gnau V; Bongers R; van den Bogaard P; Kosters H; Rollema HS; de Vos WM; Siezen RJ; Jung G; Götz F; Sahl HG; Gasson MJ
    Antonie Van Leeuwenhoek; 1996 Feb; 69(2):161-69. PubMed ID: 8775976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nisin as a model food preservative.
    Hansen JN
    Crit Rev Food Sci Nutr; 1994; 34(1):69-93. PubMed ID: 8142045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioengineering of the model lantibiotic nisin.
    Field D; Cotter PD; Ross RP; Hill C
    Bioengineered; 2015; 6(4):187-92. PubMed ID: 25970137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetics of subtilin and nisin biosyntheses: biosynthesis of lantibiotics.
    Entian KD; de Vos WM
    Antonie Van Leeuwenhoek; 1996 Feb; 69(2):109-17. PubMed ID: 8775971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lantibiotics, a class of ribosomally synthesized peptide antibiotics].
    Entian KD; Klein C
    Naturwissenschaften; 1993 Oct; 80(10):454-60. PubMed ID: 8264800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elucidation of the primary structure of the lantibiotic epilancin K7 from Staphylococcus epidermidis K7. Cloning and characterisation of the epilancin-K7-encoding gene and NMR analysis of mature epilancin K7.
    van de Kamp M; van den Hooven HW; Konings RN; Bierbaum G; Sahl HG; Kuipers OP; Siezen RJ; de Vos WM; Hilbers CW; van de Ven FJ
    Eur J Biochem; 1995 Jun; 230(2):587-600. PubMed ID: 7607233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing the Antimicrobial Activity of Nisin-Based Lantibiotics against Gram-Negative Pathogens.
    Li Q; Montalban-Lopez M; Kuipers OP
    Appl Environ Microbiol; 2018 Jun; 84(12):. PubMed ID: 29625984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering a disulfide bond and free thiols in the lantibiotic nisin Z.
    van Kraaij C; Breukink E; Rollema HS; Bongers RS; Kosters HA; de Kruijff B; Kuipers OP
    Eur J Biochem; 2000 Feb; 267(3):901-9. PubMed ID: 10651829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biosynthesis of the lantibiotics epidermin, gallidermin, Pep5 and epilancin K7.
    Bierbaum G; Götz F; Peschel A; Kupke T; van de Kamp M; Sahl HG
    Antonie Van Leeuwenhoek; 1996 Feb; 69(2):119-127. PubMed ID: 8775972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of lantibiotic gene clusters and encoded proteins.
    Siezen RJ; Kuipers OP; de Vos WM
    Antonie Van Leeuwenhoek; 1996 Feb; 69(2):171-84. PubMed ID: 8775977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posttranslationally modified bacteriocins--the lantibiotics.
    Guder A; Wiedemann I; Sahl HG
    Biopolymers; 2000; 55(1):62-73. PubMed ID: 10931442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maturation pathway of nisin and other lantibiotics: post-translationally modified antimicrobial peptides exported by gram-positive bacteria.
    de Vos WM; Kuipers OP; van der Meer JR; Siezen RJ
    Mol Microbiol; 1995 Aug; 17(3):427-37. PubMed ID: 8559062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery, Production and Modification of Five Novel Lantibiotics Using the Promiscuous Nisin Modification Machinery.
    van Heel AJ; Kloosterman TG; Montalban-Lopez M; Deng J; Plat A; Baudu B; Hendriks D; Moll GN; Kuipers OP
    ACS Synth Biol; 2016 Oct; 5(10):1146-1154. PubMed ID: 27294279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering of a novel thioether bridge and role of modified residues in the lantibiotic Pep5.
    Bierbaum G; Szekat C; Josten M; Heidrich C; Kempter C; Jung G; Sahl HG
    Appl Environ Microbiol; 1996 Feb; 62(2):385-92. PubMed ID: 8593044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual role of GdmH in producer immunity and secretion of the Staphylococcal lantibiotics gallidermin and epidermin.
    Hille M; Kies S; Götz F; Peschel A
    Appl Environ Microbiol; 2001 Mar; 67(3):1380-3. PubMed ID: 11229936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The biology of lantibiotics from the lacticin 481 group is coming of age.
    Dufour A; Hindré T; Haras D; Le Pennec JP
    FEMS Microbiol Rev; 2007 Mar; 31(2):134-67. PubMed ID: 17096664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lantibiotics: mode of action, biosynthesis and bioengineering.
    Bierbaum G; Sahl HG
    Curr Pharm Biotechnol; 2009 Jan; 10(1):2-18. PubMed ID: 19149587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple activities in lantibiotics--models for the design of novel antibiotics?
    Pag U; Sahl HG
    Curr Pharm Des; 2002; 8(9):815-33. PubMed ID: 11945173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the leader and structural regions of prelantibiotic peptides as assessed by expressing nisin-subtilin chimeras in Bacillus subtilis 168, and characterization of their physical, chemical, and antimicrobial properties.
    Chakicherla A; Hansen JN
    J Biol Chem; 1995 Oct; 270(40):23533-9. PubMed ID: 7559517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into in vivo activities of lantibiotics from gallidermin and epidermin mode-of-action studies.
    Bonelli RR; Schneider T; Sahl HG; Wiedemann I
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1449-57. PubMed ID: 16569864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.